cefiderocol
NDA- Indications
- Gram-negative bacterial infections
Company intelligence / Profile preview
Ping An-Shionogi was established as a joint venture between Shionogi & Co., Ltd. and Ping An Life Insurance Company to combine pharmaceutical R&D with digital healthcare platforms. The company focused on leveraging real-world data, AI technology, and digital tools to accelerate drug development—especially for metabolic diseases, infectious diseases like those treatable by cefiderocol, and CNS disorders. Notable achievements include advancing new drugs through regulatory processes in China/Singapore. As of December 2024, the joint ventures are being dissolved with Shionogi taking full control.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ping An-Shionogi Co., Ltd..